Clinical Trials Browser

Completed × Breast Neoplasms × palbociclib × Clear all

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

49 enrolled 14 charts

Breast Neoplasms

NCT04671615 2025-12-10

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

559 enrolled 26 charts

Breast Neoplasms

NCT04735367 2025-12-09

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

42 enrolled 7 charts

Breast Neoplasms

NCT02630693 2025-11-25

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02297438 2025-10-27

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Phase 3 Completed

340 enrolled 29 charts

Breast Neoplasms, Neoplasm Metastasis

NCT07096024 2025-08-28

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

Breast Neoplasms

NCT05399329 2025-07-11

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Breast Neoplasms

NCT06307457 2025-06-29

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

604 enrolled 20 charts

Breast Neoplasms

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2 Completed

162 enrolled 12 charts

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

Phase 2 Completed

36 enrolled 17 charts

Breast Neoplasms

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03644186 2024-12-13

TOUCH

Phase 2 Completed

147 enrolled 11 charts

Breast Neoplasms

NCT06525675 2024-12-13

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Breast Neoplasms

NCT02491983 2024-12-09

PARSIFAL

Phase 2 Completed

486 enrolled 15 charts

Breast Neoplasms

NCT01740427 2024-11-14

PALOMA-2

Phase 3 Completed

666 enrolled 22 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1 Completed

35 enrolled 19 charts

Breast Neoplasms

NCT02389842 2024-09-26

PIPA

Phase 1 Completed

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Breast Neoplasms

NCT02913430 2024-09-23

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Phase EARLY_PHASE1 Completed

7 enrolled 13 charts

Breast Neoplasms

NCT04176354 2024-08-23

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

813 enrolled 11 charts

Breast Neoplasms

NCT03560531 2024-08-09

A Study of ZN-c5 in Subjects With Breast Cancer

Phase 1/2 Completed

181 enrolled 36 charts

Breast Neoplasms

NCT05361655 2024-06-07

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

2,888 enrolled 17 charts

Breast Neoplasms

NCT02599714 2024-06-06

PASTOR

Phase 1 Completed

Breast Neoplasms

NCT06003114 2024-05-16

A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

Phase 2 Completed

Breast Neoplasms

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

55 enrolled 15 charts

Breast Neoplasms

NCT02536742 2024-02-26

PYTHIA

Phase 2 Completed

124 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05584644 2023-12-19

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

150 enrolled 26 charts

Breast Neoplasms

NCT01864746 2023-12-12

PENELOPE-B

Phase 3 Completed

1,250 enrolled 12 charts

Breast Neoplasms

NCT03054363 2023-11-13

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Breast Neoplasms

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03809988 2023-09-07

PALMIRA

Phase 2 Completed

Breast Neoplasms

NCT04916509 2023-06-06

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Breast Neoplasms

NCT03285568 2023-03-31

Patterns of Prescribing and Monitoring of Palbociclib

Breast Neoplasms

NCT03921866 2023-03-17

ROIS

191 enrolled 91 charts

Breast Neoplasms

NCT02894398 2023-03-13

INGE-B

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03447132 2023-03-10

SAFIA

Phase 3 Completed

Breast Neoplasms

NCT03455270 2022-12-15

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT02448771 2022-10-24

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Phase 1/2 Completed

36 enrolled 28 charts

Breast Neoplasms

NCT02806050 2022-10-12

Palbociclib and FES PET

Phase 2 Completed

Breast Neoplasms

NCT04874025 2022-08-08

PALBOSPAIN

Breast Neoplasms

NCT02679755 2022-07-27

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 4 Completed

252 enrolled 15 charts

Breast Neoplasms

NCT02684032 2022-07-27

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT03184090 2022-06-21

BioPER

Phase 2 Completed

Breast Neoplasms

NCT03628066 2022-04-20

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT02384239 2022-03-16

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

Phase 2 Completed

70 enrolled 16 charts

Breast Neoplasms

NCT01976169 2022-02-08

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Phase 1 Completed

Breast Neoplasms

NCT02600923 2022-01-20

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Phase 3 Completed

131 enrolled 12 charts

Breast Neoplasms